1 Regal M, Paramo C, Sierra SM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 2001; 55: 735–40.
2 Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 2000; 85: 1420–25.
3 Olsson DS, Nilsson AG, Bryngelsson I-L, Trimpou P, Johannsson G, Andersson E. Excess mortality in women and young adults with nonfunctioning pituitary adenoma: a Swedish nationwide study. J Clin Endocrinol Metab 2015; 100: 2651–58.
4 Raappana A, Koivukangas J, Ebeling T, Pirila T. Incidence of pituitary adenomas in northern Finland in 1992–2007. J Clin Endocrinol Metab 2010; 95: 4268–75.
5 Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001; 357: 425–31.
6 Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev 2010; 31: 301–42.
7 Gaillard RC, Mattsson AF, Akerblad A-C, et al. Overall and cause-specifi c mortality in GH-defi cient adults on GH replacement. Eur J Endocrinol 2012; 166: 1069–77.
8 Van Bunderen CC, van Nieuwpoort IC, Arwert LI, et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone defi ciency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab 2011; 96: 3151–59.
9 Burman P, Mattsson AF, Johannsson G, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab 2013; 98: 1466–75.
10 Hartman ML, Xu R, Crowe BJ, et al. Prospective safety surveillance of GH-defi cient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab 2013; 98: 980–88.
11 Tanriverdi F, Dokmetas HS, Kebapcı N, et al. Etiology of hypopituitarism in tertiary care institutions in Turkish population: analysis of 773 patients from Pituitary Study Group database. Endocrine 2014; 47: 198–205.
12 Nomikos P, Ladar C, Fahlbusch R, Buchfelder M. Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas—a study on 721 patients. Acta Neurochir (Wien) 2004; 146: 27–35.
13 Arafah BM. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1986; 62: 1173–79.
14 Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR. The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. J Clin Endocrinol Metab 2000; 85: 1789–93.
15 Olsson DS, Andersson E, Bryngelsson I-L, Nilsson AG, Johannsson G. Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden. J Clin Endocrinol Metab 2015;100: 467–74.
16 Swearingen B. Update on pituitary surgery. J Clin Endocrinol Metab 2012; 97: 1073–81.
17 Barker FG, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 2003; 88: 4709–19.
18 Arafah BM, Kailani SH, Nekl KE, Gold RS, Selman WR. Immediate recovery of pituitary function after transsphenoidal resection of pituitary macroadenomas. J Clin Endocrinol Metab 1994;79: 348–54.
19 Darzy KH, Shalet SM. Hypopituitarism following radiotherapy revisited. Endocr Dev 2009; 15: 1–24.
20 Marek J, Jezkova J, Hana V, et al. Is it possible to avoid hypopituitarism after irradiation of pituitary adenomas by the Leksell gamma knife? Eur J Endocrinol 2011; 164: 169–78.
21 Roug S, Rasmussen AK, Juhler M, et al. Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit. Eur J Endocrinol 2010; 162: 685–94.
22 Schalin-Jantti C, Valanne L, Tenhunen M, et al. Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: a 5.25-year follow-up study. Clin Endocrinol (Oxf) 2010; 73: 72–77.
23 Xu Z, Lee Vance M, Schlesinger D, Sheehan JP. Hypopituitarism after stereotactic radiosurgery for pituitary adenomas. Neurosurgery 2013; 72: 630–37.
24 Cohen-Inbar O, Ramesh A, Xu Z, Vance ML, Schlesinger D, Sheehan JP. Gamma knife radiosurgery in patients with persistent acromegaly or Cushing’s disease: long-term risk of hypopituitarism. Clin Endocrinol (Oxf) 2016; 84: 524–31.
25 Tanriverdi F, Schneider HJ, Aimaretti G, Masel BE, Casanueva FF, Kelestimur F. Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. Endocr Rev 2015;36: 305–42.
26 Fernandez-Rodriguez E, Bernabeu I, Castro AI, Kelestimur F, Casanueva FF. Hypopituitarism following traumatic brain injury: determining factors for diagnosis. Front Endocrinol (Lausanne) 2011; 2: 25.
27 Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla G-K, Ghigo E. Hypopituitarism. Lancet 2007; 369: 1461–70.
28 Capatina C, Inder W, Karavitaki N, Wass JAH. Management of endocrine disease: pituitary tumour apoplexy. Eur J Endocrinol 2015;172: R179–90.
29 Briet C, Salenave S, Chanson P. Pituitary apoplexy. Endocrinol Metab Clin North Am 2015; 44: 199–209.
30 Diri H, Tanriverdi F, Karaca Z, et al. Extensive investigation of 114 patients with Sheehan’s syndrome: a continuing disorder. Eur J Endocrinol 2014; 171: 311–18.
31 Ramiandrasoa C, Castinetti F, Raingeard I, et al. Delayed diagnosis of Sheehan’s syndrome in a developed country: a retrospective cohort study. Eur J Endocrinol 2013; 169: 431–38.
32 Khajeh L, Blijdorp K, Neggers SJ, Ribbers GM, Dippel DW, van Kooten F. Hypopituitarism after subarachnoid haemorrhage, do we know enough? BMC Neurol 2014; 14: 205.
33 Kronvall E, Valdemarsson S, Saveland H, Nilsson OG. High prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a long-term prospective study using dynamic endocrine testing. World Neurosurg 2015; 83: 574–82.
34 Hannon MJ, Behan LA, O’Brien MM, et al. Chronic hypopituitarism is uncommon in survivors of aneurysmal subarachnoid haemorrhage. Clin Endocrinol (Oxf) 2015; 82: 115–21.
35 Kaltsas GA, Powles TB, Evanson J, et al. Hypothalamo–pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab 2000; 85: 1370–76.
36 Wilson V, Mallipedhi A, Stephens JW, Redfern RM, Price DE. The causes of hypopituitarism in the absence of abnormal pituitary imaging. QJM 2014; 107: 21–24.
37 Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F. Pregnancy and pituitary disorders. Eur J Endocrinol 2010; 162: 453–75.
38 Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014;99: 4078–85.
39 Albarel F, Gaudy C, Castinetti F, et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 2015;172: 195–204.
40 McCabe MJ, Dattani MT. Genetic aspects of hypothalamic and pituitary gland development. Handb Clin Neurol 2014; 124: 3–15.
41 Alatzoglou KS, Webb EA, Le Tissier P, Dattani MT. Isolated growth hormone deficiency (GHD) in childhood and adolescence: recent advances. Endocr Rev 2014; 35: 376–432.
42 Bancalari RE, Gregory LC, McCabe MJ, Dattani MT. Pituitary gland development: an update. Endocr Dev 2012; 23: 1–15.
43 Kalra S, Dhanwal D, Khadilkar V. Hypopituitarism in the tropics. Indian J Endocrinol Metab 2011; 15 (suppl 3): S151–53.
44 Golay V, Roychowdhary A, Dasgupta S, Pandey R. Hypopituitarism in patients with vasculotoxic snake bite envenomation related acute kidney injury: a prospective study on the prevalence and outcomes of this complication. Pituitary 2014; 17: 125–31.
45 Rajasekaran S, Vanderpump M, Baldeweg S, et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf) 2011; 74: 9–20.
46 Capatina C, Inder W, Karavitaki N, Wass JA. Management of endocrine disease: pituitary tumour apoplexy. Eur J Endocrinol 2015;172: R179–90.
47 Wieringa GE, Sturgeon CM, Trainer PJ. The harmonisation of growth hormone measurements: taking the next steps. Clin Chim Acta 2014; 432: 68–71.
48 Monaghan PJ, Keevil BG, Stewart PM, Trainer PJ. Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond. J Clin Endocrinol Metab 2014; 99: 4434–37.
49 Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab 2013; 98: 3971–73.
50 Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 2014;99: 1712–21.
51 Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen defi ciency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95: 2536–59.
52 Kommunehospital A. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) defi ciency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab 2000; 85: 3990–93.
53 Ho KKY. Consensus guidelines for the diagnosis and treatment of adults with GH defi ciency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007; 157: 695–700.
54 Hartman ML, Crowe BJ, Biller BMK, Ho KKY, Clemmons DR, Chipman JJ. Which patients do not require a GH stimulation test for the diagnosis of adult GH defi ciency? J Clin Endocrinol Metab 2002; 87: 477–85.
55 Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone defi ciency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 1587–609.
56 Aimaretti G, Corneli G, Razzore P, et al. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH defi ciency in adults. J Clin Endocrinol Metab 1998;83: 1615–18.
57 Darzy KH, Aimaretti G, Wieringa G, Gattamaneni HR, Ghigo E, Shalet SM. The usefulness of the combined growth hormone (GH)-releasing hormone and arginine stimulation test in the diagnosis of radiation-induced GH defi ciency is dependent on the post-irradiation time interval. J Clin Endocrinol Metab 2003;88: 95–102.
58 Dichtel LE, Yuen KCJ, Bredella MA, et al. Overweight/obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone defi ciency. J Clin Endocrinol Metab 2014;99: 4712–19.
59 Nieman LK. Dynamic evaluation of adrenal hypofunction. J Endocrinol Invest 2003; 26 (suppl 7): 74–82.
60 Maghnie M, Uga E, Temporini F, et al. Evaluation of adrenal function in patients with growth hormone defi ciency and hypothalamic–pituitary disorders: comparison between insulin induced hypoglycemia, low-dose ACTH, standard ACTH and CRH stimulation tests. Eur J Endocrinol 2005; 152: 735–41.
61 Chitale A, Musonda P, McGregor AM, Dhatariya KK. Determining the utility of the 60 min cortisol measurement in the short synacthen test. Clin Endocrinol (Oxf) 2013; 79: 14–19.
62 Society for Endocrinology. Position statement on the use of synthetic ACTH (Synacthen) in patients with a history of asthma. http://www.endocrinology.org/policy/docs/11-09_syntheticACTH_in_patients_with_asthma.pdf (accessed March 12, 2016).
63 Crowley RK, Argese N, Tomlinson JW, Stewart PM. Central hypoadrenalism. J Clin Endocrinol Metab 2014; 99: 4027–36.
64 Persani L. Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab 2012; 97: 3068–78.
65 Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002; 87: 1068–72.
66 Goede SL, Leow MK-S. General error analysis in the relationship between free thyroxine and thyrotropin and its clinical relevance. Comput Math Methods Med 2013; 2013: 831275.
67 Jostel A, Ryder WDJ, Shalet SM. The use of thyroid function tests in the diagnosis of hypopituitarism: defi nition and evaluation of the TSH Index. Clin Endocrinol (Oxf) 2009; 71: 529–34.
68 Mukherjee A, Murray RD, Columb B, Gleeson HK, Shalet SM. Acquired prolactin defi ciency indicates severe hypopituitarism in patients with disease of the hypothalamic–pituitary axis. Clin Endocrinol (Oxf) 2003; 59: 743–48.
69 Mukherjee A, Ryder WDJ, Jostel A, Shalet SM. Prolactin deficiency is independently associated with reduced insulin-like growth factor I status in severely growth hormone-defi cient adults. J Clin Endocrinol Metab 2006; 91: 2520–25.
70 Mukherjee A, Helbert M, Davis J, Shalet S. Immune function in hypopituitarism: time to reconsider? Clin Endocrinol (Oxf) 2010;73: 425–31.
71 Fenske W, Allolio B. Current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review. J Clin Endocrinol Metab 2012; 97: 3426–37.
72 Fenske W, Quinkler M, Lorenz D, et al. Copeptin in the diff erential diagnosis of the polydipsia-polyuria syndrome—revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab 2011;96: 1506–15.
73 Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112–19.
74 Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973; 52: 2340–52.
75 Timper K, Fenske W, Kuhn F, et al. Diagnostic accuracy of copeptin in the diff erential diagnosis of the polyuria-polydipsia syndrome: a prospective multicenter study. J Clin Endocrinol Metab 2015;100: 2268–74.
76 Bladowska J, Są siadek M. Diagnostic imaging of the pituitary and parasellar region. In: Rahimi-Movaghar V, ed. Pituitary adenomas. Rijeka: InTech, 2012: 13–32.
77 Cuesta M, Gupta S, Salehmohamed R, et al. Heterogenous patterns of recovery of thirst in adult patients with adipsic diabetes insipidus. QJM 2015; published online Sept 25. DOI: 10.1093/qjmed/hcv175.
78 Eisenberg Y, Frohman LA. Adipsic diabetes insipidus: a review. Endocr Pract 2016; 22: 76–83.
79 Clayton PE, Shalet SM. Dose dependency of time of onset of radiation induced growth hormone defi ciency. J Pediatr 1991; 118: 226–28.
80 Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insuffi ciency—a worldwide patient survey. BMC Endocr Disord 2012; 12: 8.
81 Besser GM, Jeff coate WJ. Endocrine and metabolic diseases. Adrenal diseases. Br Med J 1976; 1: 448–51.
82 Kraan GP, Dullaart RP, Pratt JJ, Wolthers BG, Drayer NM, De Bruin R. The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not signifi cantly diff erent. J Clin Endocrinol Metab 1998; 83: 1247–52.
83 Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006; 91: 3954–61.
84 Agha A, Liew A, Finucane F, et al. Conventional glucocorticoid replacement overtreats adult hypopituitary patients with partial ACTH defi ciency. Clin Endocrinol (Oxf) 2004; 60: 688–93.
85 Lamia KA, Papp SJ, Yu RT, et al. Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. Nature 2011; 480: 552–56.
86 Plat L, Leproult R, L’Hermite-Baleriaux M, et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab 1999;84: 3082–92.
87 Whitaker MJ, Debono M, Huatan H, Merke DP, Arlt W, Ross RJ. An oral multiparticulate, modifi ed-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. Clin Endocrinol 2014; 80: 554–61.
88 Oksnes M, Bjornsdottir S, Isaksson M, et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison’s disease: a randomized clinical trial. J Clin Endocrinol Metab 2014; 99: 1665–74.
89 Johannsson G, Nilsson AG, Bergthorsdottir R, et al. Improved cortisol exposure–time profi le and outcome in patients with adrenal insuffi ciency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 2012; 97: 473–81.
90 Hahner S, Spinnler C, Fassnacht M, et al. High incidence of adrenal crisis in educated patients with chronic adrenal insuffi ciency: a prospective study. J Clin Endocrinol Metab 2015;100: 407–16.
91 Swords FM, Carroll PV, Kisalu J, Wood PJ, Taylor NF, Monson JP. The eff ects of growth hormone defi ciency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement. Clin Endocrinol (Oxf) 2003; 59: 613–20.
92 Weaver JU, Thaventhiran L, Noonan K, et al. The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol (Oxf) 1994;41: 639–48.
93 Giavoli C, Libe R, Corbetta S, et al. Eff ect of recombinant human growth hormone (GH) replacement on the hypothalamic–pituitary–adrenal axis in adult GH-defi cient patients. J Clin Endocrinol Metab 2004; 89: 5397–401.
94 Miller KK, Sesmilo G, Schiller A, Schoenfeld D, Burton S, Klibanski A. Androgen defi ciency in women with hypopituitarism. J Clin Endocrinol Metab 2001; 86: 561–67.
95 Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insuffi ciency. N Engl J Med 1999; 341: 1013–20.
96 Johannsson G, Sverrisdottir YB, Ellegard L, Lundberg PA, Herlitz H. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J Clin Endocrinol Metab 2002; 87: 1743–49.
97 Brooke AM, Kalingag LA, Miraki-Moud F, et al. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. J Clin Endocrinol Metab 2006; 91: 3773–79.
98 Brooke AM, Kalingag LA, Miraki-Moud F, et al. Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement. Clin Endocrinol (Oxf) 2006; 65: 673–80.
99 Jorgensen JOL, Pedersen SA, Laurberg P, Weeke J, Sakkebak NE, Christiansen JS. Eff ects of growth hormone therapy on thyroid function of growth hormone-defi cient adults with and without concomittant thyroxine-substituted central hypothyroidism. J Clin Endocrinol Metab 1989; 69: 1127–32.
100 Carrozza V, Csako G, Yanovski JA, et al. Levothyroxine replacement therapy in central hypothyroidism: a practice report. Pharmacotherapy 1999; 19: 349–55.
101 Slawik M, Klawitter B, Meiser E, et al. Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab 2007; 92: 4115–22.
102 Alexopoulou O, Beguin C, De Nayer P, Maiter D. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol 2004; 150: 1–8.
103 Shimon I, Cohen O, Lubetsky A, Olchovsky D. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid 2002; 12: 823–27.
104 Filipsson Nystrom H, Feldt-Rasmussen U, Kourides I, et al. The metabolic consequences of thyroxine replacement in adult hypopituitary patients. Pituitary 2012; 15: 495–504.
105 Klose M, Marina D, Hartoft-Nielsen M-L, et al. Central hypothyroidism and its replacement have a signifi cant infl uence on cardiovascular risk factors in adult hypopituitary patients. J Clin Endocrinol Metab 2013; 98: 3802–10.
106 Ferretti E, Persani L, Jaff rain-Rea ML, Giambona S, Tamburrano G, Beck-Peccoz P. Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab 1999; 84: 924–29.
107 Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev 2004; 25: 693–721.
108 Wiren L, Boguszewski CL, Johannsson G. Growth hormone (GH) replacement therapy in GH-defi cient women during pregnancy. Clin Endocrinol (Oxf) 2002; 57: 235–39.
109 Vila G, Akerblad AC, Mattsson AF, et al. Pregnancy outcomes in women with growth hormone defi ciency. Fertil Steril 2015;104: 1210–17.
110 Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E. Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. Eur J Endocrinol 2002; 147: 617–24.
111 Liu PY, Baker HW, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-defi cient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab 2009;94: 801–08.
112 Drake WM, Howell SJ, Monson JP, Shalet SM. Optimizing GH therapy in adults and children. Endocr Rev 2001; 22: 425–50.
113 Maison P, Griffi n S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-defi cient adults: a meta analysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 2004; 89: 2192–99.
114 Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone (GH) defi ciency with recombinant human GH. J Clin Endocrinol Metab 1993; 76: 309–17.
115 Burman P, Broman JE, Hetta J, et al. Quality of life in adults with growth hormone (GH) defi ciency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995; 80: 3585–90.
116 Arwert LI, Veltman DJ, Deijen JB, van Dam PS, Drent ML. Eff ects of growth hormone substitution therapy on cognitive functioning in growth hormone defi cient patients: a functional MRI study. Neuroendocrinology 2006; 83: 12–19.
117 Baum HB, Katznelson L, Sherman JC, et al. Eff ects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH defi ciency. J Clin Endocrinol Metab 1998; 83: 3184–89.
118 Drake WM, Coyte D, Camacho-Hubner C, et al. Opimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998; 83: 3913–19.
119 Johannsson G, Rosen T, Bengtsson BA. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf) 1997; 47: 571–81.
120 Wiren L, Bengtsson BA, Johannsson G. Benefi cial eff ects of long-term GH replacement therapy on quality of life in adults with GH defi ciency. Clin Endocrinol 1998; 48: 613–20.
121 Stochholm K, Johannsson G. Reviewing the safety of GH replacement therapy in adults. Growth Horm IGF Res 2015; 25: 149–57.
122 Johansson J-O, Fowelin J, Landin K, Lager I, Bengtsson B-A. Growth hormone-defi cient adults are insulin-resistant. Metabolism 1995; 44: 1126–29.
123 Attanasio AF, Jung H, Mo D, et al. Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J Clin Endocrinol Metab 2011; 96: 2255–61.
124 Luger A, Mattsson AF, Koltowska-Haggstrom M, et al. Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-defi cient subjects during growth hormone replacement therapy: a long-term observational study. Diabetes Care 2012;35: 57–62.
125 Child CJ, Zimmermann AG, Woodmansee WW, et al. Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. Eur J Endocrinol 2011; 165: 217–23.
126 Olsson DS, Buchfelder M, Schlaff er S, et al. Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. Eur J Endocrinol 2009; 161: 663–69.
127 Olsson DS, Buchfelder M, Wiendieck K, et al. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. Eur J Endocrinol 2012; 166: 1061–68.
128 Curran AJ, Peacey SR, Shalet SM. Is maternal growth hormone essential for a normal pregnancy? Eur J Endocrinol 1998; 139: 54–58.
129 Shalet SM. Extensive expertise in endocrinology: UK stance on adult GH replacement: the economist vs the endocrinologist. Eur J Endocrinol 2013; 169: R81–87.
130 Koulouri O, Auldin MA, Agarwal R, et al. Diagnosis and treatment of hypothyroidism in TSH defi ciency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. Clin Endocrinol (Oxf) 2011; 74: 744–49.
131 Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005;152: 165–70.
132 Chemaitilly W, Li Z, Huang S, et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol 2015; 33: 492–500.
ComentariosUsted debe estar registrado para expresar su opinión. Si ya es usuario de IntraMed o desea registrase como nuevo usuario, ingrese aquí